Overview
- The company now expects $1.6 billion to $2.0 billion in 2025 revenue after lowering the top end by $200 million.
- Third-quarter revenue totaled about $1.0 billion, a 45% year-over-year decline that still topped analyst estimates.
- Moderna reported a net loss of $0.51 per share, far smaller than the roughly $2 per-share loss Wall Street expected.
- Adjusted operating expense guidance for 2025 was cut by $700 million to a range of $5.2 billion to $5.4 billion.
- U.S. policy changes that narrowed COVID shot access weighed on demand, while RSV sales were $2 million and the CMV program was halted as the COVID/flu combo awaits FDA guidance.